Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for cancer, and its news flow reflects the evolution of this strategy. Company announcements highlight progress with KOMZIFTI (ziftomenib), an oral menin inhibitor approved in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
News items for KURA commonly cover regulatory milestones, clinical data and commercial updates. Recent releases describe full FDA approval of KOMZIFTI, its addition to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a Category 2A recommended option for relapsed or refractory NPM1-mutated AML, and the start of U.S. commercial sales. Kura also reports on its collaboration with Kyowa Kirin, including milestone payments tied to clinical and commercial events.
Investors following KURA news can expect detailed coverage of clinical trial readouts from programs such as KOMET-001, KOMET-007 and KOMET-017, which evaluate ziftomenib across newly diagnosed and relapsed or refractory AML, often in combination with regimens like cytarabine/daunorubicin and venetoclax/azacitidine. Additional news addresses the company’s farnesyl transferase inhibitor programs, darlifarnib and tipifarnib, and their activity in solid tumors.
Kura’s press releases also include corporate updates such as financial results, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in scientific and investor conferences. For readers tracking KURA, this news page offers a centralized view of key developments in its precision oncology pipeline, regulatory interactions, collaborations and commercialization activities.
Kura Oncology, Inc. announced the granting of inducement awards in the form of nonstatutory stock options to six new employees under the 2023 Inducement Option Plan. The stock options will allow the purchase of 67,950 shares of common stock at an exercise price of $20.28 per share. The options will vest over four years, with 25% vesting after one year, and the rest vesting monthly over 36 months, contingent on the employees' continued service relationship.
Kura Oncology reported first quarter 2024 financial results, highlighting Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML, positive preliminary combination data, and first patient dosing with KO-2806 and cabozantinib. The company has $527 million in cash, cash equivalents, and investments, ensuring runway into 2027. Financially, research and development expenses increased to $36.3 million, while general and administrative expenses rose to $18.2 million. The net loss for Q1 2024 was $49.5 million. Management expects current funds to last into 2027.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.